Name
Purdue University Globle
NU553 Advanced Pharmacology and Pharmacotherapeutics
Prof. Name
Date
Asthma, chronic obstructive pulmonary disease (COPD), pneumonia, tuberculosis (TB), and tobacco dependence require evidence-based pharmacologic management tailored to the patient’s diagnosis, disease severity, and clinical needs. Asthma is primarily managed with inhaled corticosteroid-containing therapy to control airway inflammation, while COPD treatment relies on bronchodilators, smoking cessation, and supportive care. Pneumonia requires antimicrobial treatment based on the likely pathogen and severity, and tuberculosis requires prolonged multidrug therapy to prevent drug resistance. Tobacco cessation medications and behavioral counseling further improve respiratory health and reduce disease progression.
This nursing pharmacology study guide explains the major respiratory medications, their mechanisms of action, clinical uses, adverse effects, and essential patient education. It also reviews current asthma treatment principles, COPD management, pneumonia antibiotics, tuberculosis therapy, and smoking cessation strategies.
Asthma is a chronic inflammatory disease of the airways characterized by variable respiratory symptoms and fluctuating expiratory airflow limitation. Airway inflammation, bronchial hyperresponsiveness, and bronchoconstriction contribute to symptoms such as wheezing, coughing, chest tightness, and shortness of breath.
Unlike COPD, asthma commonly involves variable airflow limitation that may improve spontaneously or with treatment. Symptoms can be triggered by allergens, respiratory infections, exercise, smoke, and other environmental factors.
The primary goals of asthma pharmacologic management are to:
Control daytime and nighttime symptoms.
Prevent acute exacerbations and hospitalizations.
Maintain normal or near-normal lung function.
Reduce the need for rescue medication.
Minimize medication-related adverse effects.
Asthma severity and control should be assessed regularly. Treatment is adjusted according to symptom frequency, exacerbation risk, inhaler technique, medication adherence, and response to therapy.
Short-acting beta-agonists (SABAs) are bronchodilators that stimulate beta-2 adrenergic receptors in airway smooth muscle. This relaxes the muscles surrounding the bronchi and produces rapid relief of bronchoconstriction.
Albuterol (salbutamol): Commonly used for rapid relief of bronchospasm.
Levalbuterol: A related short-acting beta-agonist used in selected patients.
SABAs may be used for acute symptoms or exercise-related bronchospasm. However, current asthma guidelines do not recommend SABA-only treatment as the preferred long-term approach because SABAs relieve bronchoconstriction without adequately treating underlying airway inflammation.
Common adverse effects include tremor, nervousness, palpitations, and tachycardia. Nurses should assess respiratory status, heart rate, symptom relief, and frequency of rescue inhaler use.
Frequent SABA use may indicate poorly controlled asthma and the need to reassess the patient’s controller therapy.
Long-acting beta-agonists provide prolonged bronchodilation by stimulating beta-2 adrenergic receptors. They are used to improve symptom control and reduce bronchoconstriction over an extended period.
Examples include:
Salmeterol.
Formoterol.
Vilanterol, used in selected combination inhalers.
LABAs should not be used alone for asthma treatment. They must be prescribed with an inhaled corticosteroid because bronchodilation alone does not adequately control airway inflammation.
Common combination products include:
Fluticasone/salmeterol.
Budesonide/formoterol.
Mometasone/formoterol.
Formoterol-containing ICS combinations may be used in guideline-directed maintenance-and-reliever therapy when appropriate.
LABAs are important maintenance medications for COPD. They improve airflow, reduce breathlessness, and may improve exercise tolerance. Unlike asthma, LABA monotherapy is an accepted treatment option for many patients with COPD.
Nurses should reinforce that maintenance inhalers are taken according to the prescribed schedule and are not necessarily intended for immediate relief of severe acute symptoms.
Inhaled corticosteroids are the primary anti-inflammatory medications used in persistent asthma. They reduce airway inflammation, bronchial hyperresponsiveness, and the risk of exacerbations.
Common ICS medications include:
Fluticasone.
Budesonide.
Beclomethasone.
Mometasone.
Regular use can reduce asthma symptoms, improve lung function, decrease exacerbations, and reduce the need for systemic corticosteroids.
The most common local adverse effects include:
Oral candidiasis.
Dysphonia or hoarseness.
Throat irritation.
Patients should rinse their mouth with water after using an inhaled corticosteroid and spit out the water. A spacer may help reduce medication deposition in the mouth when using an appropriate metered-dose inhaler.
Patients should understand that ICS medications are controller therapies. They are not intended to provide immediate relief during a severe asthma attack.
Adherence is essential even when the patient feels well because asthma inflammation may persist despite minimal symptoms.
Long-acting muscarinic antagonists block muscarinic receptors in the airways, reducing cholinergic-mediated bronchoconstriction and promoting sustained bronchodilation.
Tiotropium.
Umeclidinium.
Glycopyrrolate.
Aclidinium.
LAMAs are widely used as maintenance therapy for COPD. Tiotropium may also be added to asthma treatment for selected patients whose symptoms remain uncontrolled despite optimized inhaled corticosteroid-containing therapy.
LAMAs do not provide immediate relief during acute bronchospasm. Patients should use their prescribed rescue medication when rapid symptom relief is needed.
Possible adverse effects include dry mouth, constipation, urinary retention, and blurred vision. Patients with glaucoma or urinary retention should discuss these conditions with their healthcare provider.
Asthma treatment is individualized and follows a stepwise approach. The goal is to achieve and maintain control using the lowest effective medication intensity.
The Global Initiative for Asthma recommends ICS-containing therapy for adults and adolescents with asthma. Its preferred Track 1 approach uses low-dose ICS-formoterol as the reliever at appropriate treatment steps, with maintenance ICS-formoterol at higher steps when indicated.
Key principles include:
Avoiding SABA-only treatment in adults and adolescents.
Using ICS-containing medication to reduce exacerbation risk.
Assessing inhaler technique and adherence before stepping up therapy.
Adjusting treatment based on symptom control and risk.
The National Asthma Education and Prevention Program provides stepwise recommendations for asthma management. Its focused updates address inhaled corticosteroids, ICS-formoterol therapy, long-acting muscarinic antagonists, and other treatment strategies.
The NAEPP and GINA guidelines differ in some treatment recommendations, particularly in how reliever therapy is used. Clinicians should follow the guideline adopted by their practice setting.
Before changing asthma medications, clinicians should assess symptom frequency, nighttime awakenings, exacerbation history, inhaler technique, adherence, and exposure to triggers.
A personalized asthma action plan should explain how to recognize worsening symptoms, adjust prescribed medications, and seek urgent medical care.
Patient education should include:
Correct inhaler technique.
The difference between controller and rescue medications.
Trigger avoidance when appropriate.
Recognition of severe asthma symptoms.
Medication adherence.
Peak flow monitoring when clinically indicated.
Severe breathlessness, difficulty speaking, cyanosis, confusion, or poor response to rescue medication requires urgent medical evaluation.
COPD is a chronic respiratory disease characterized by persistent respiratory symptoms and airflow obstruction caused by abnormalities in the airways and/or alveoli. It is commonly associated with exposure to tobacco smoke, occupational pollutants, and other harmful inhaled substances.
Symptoms include chronic cough, sputum production, exertional dyspnea, wheezing, and reduced exercise tolerance.
Spirometry is essential for confirming COPD. A post-bronchodilator FEV1/FVC ratio below 0.70 supports the diagnosis of persistent airflow obstruction in the appropriate clinical setting.
FEV1 is used to grade airflow obstruction after COPD has been confirmed.
| COPD airflow obstruction grade | Post-bronchodilator FEV1 |
|---|---|
| GOLD 1: Mild | ≥80% predicted |
| GOLD 2: Moderate | 50–79% predicted |
| GOLD 3: Severe | 30–49% predicted |
| GOLD 4: Very severe | <30% predicted |
These grades describe airflow obstruction, not the entire clinical severity of COPD. Symptom burden, exacerbation history, comorbidities, and functional status also guide treatment.
Emphysema involves destruction of alveolar walls and loss of elastic recoil. This reduces the surface area available for gas exchange and contributes to air trapping.
Common clinical features include:
Progressive exertional dyspnea.
Reduced breath sounds.
Hyperinflation.
Pursed-lip breathing.
Reduced exercise tolerance.
The historical term “pink puffer” is outdated and should not be used as a diagnostic classification.
Chronic bronchitis is traditionally defined as a productive cough for at least three months in each of two consecutive years, after excluding other causes.
Patients may experience:
Chronic productive cough.
Increased sputum production.
Wheezing.
Recurrent respiratory infections.
Breathlessness.
The historical term “blue bloater” is also outdated and does not accurately classify all patients with chronic bronchitis.
COPD treatment aims to reduce symptoms, improve exercise tolerance, prevent exacerbations, and improve quality of life. Treatment may also help reduce hospitalizations and support long-term functional independence.
Smoking cessation is the most important intervention for reducing ongoing tobacco-related lung injury.
Additional nonpharmacologic measures include pulmonary rehabilitation, physical activity, vaccination, nutritional support when appropriate, and education about inhaler use.
LABAs improve airflow by relaxing airway smooth muscle. Common medications include salmeterol, formoterol, indacaterol, and olodaterol.
They are used for long-term symptom management and may be prescribed alone or in combination with a LAMA.
LAMAs such as tiotropium, umeclidinium, glycopyrrolate, and aclidinium are important maintenance bronchodilators in COPD.
They improve airflow and reduce symptoms. LAMAs are not rescue medications for sudden severe breathlessness.
Combining a LABA with a LAMA may provide greater improvement in lung function and symptom control than either medication alone.
Examples include:
Umeclidinium/vilanterol.
Tiotropium/olodaterol.
Glycopyrrolate/formoterol.
Short-acting combinations such as albuterol/ipratropium may be used for symptom relief in selected patients.
ICS medications are not routinely prescribed as monotherapy for COPD. They may be added to bronchodilator therapy for selected patients, particularly those with frequent exacerbations and features suggesting a greater likelihood of benefit.
Blood eosinophil counts and exacerbation history may help guide decisions about ICS use. ICS treatment should be individualized because it can increase the risk of pneumonia in some patients.
Theophylline is an oral bronchodilator with a narrow therapeutic index. Its use in COPD is limited because of variable drug levels, numerous drug interactions, and potentially serious toxicity.
Adverse effects may include nausea, vomiting, tremor, insomnia, tachycardia, arrhythmias, and seizures.
Nurses should monitor for toxicity and reinforce the importance of medication review when theophylline is prescribed.
A COPD exacerbation is an acute worsening of respiratory symptoms beyond normal day-to-day variation that requires additional treatment.
Management may include short-acting bronchodilators, systemic corticosteroids, antibiotics when indicated, controlled oxygen therapy, and noninvasive ventilation for selected patients.
Prednisone 40 mg orally once daily for five days is a commonly recommended regimen for many moderate-to-severe COPD exacerbations. Treatment should follow current clinical guidance and individual patient needs.
Systemic corticosteroids can shorten recovery and improve lung function. Long-term oral corticosteroid use is generally avoided in stable COPD because of significant adverse effects.
Monitor respiratory rate, oxygen saturation, breath sounds, mental status, and response to treatment. Assess for hyperglycemia, infection, fluid retention, and other corticosteroid-related effects.
Supplemental oxygen is used when clinically significant hypoxemia is present. Long-term oxygen therapy improves survival in selected patients with severe chronic resting hypoxemia.
For stable COPD, long-term oxygen is generally considered when the patient has:
PaO2 at or below approximately 55 mmHg, or oxygen saturation at or below 88%.
PaO2 of approximately 56–59 mmHg or oxygen saturation around 89% with selected complications such as pulmonary hypertension, edema from heart failure, or secondary polycythemia.
During acute exacerbations, oxygen should be titrated to the prescribed target, often 88–92% in patients at risk of hypercapnic respiratory failure.
Pneumonia is an infection of the lung parenchyma caused by bacteria, viruses, fungi, or other microorganisms. The disease may impair gas exchange and produce inflammation within the alveoli.
Common clinical manifestations include fever, cough, sputum production, dyspnea, pleuritic chest pain, fatigue, and abnormal lung sounds. Chest imaging may show infiltrates or other findings consistent with pneumonia.
Treatment depends on the suspected organism, age, comorbidities, severity of illness, local resistance patterns, and whether the infection was acquired in the community or healthcare setting.
Antibiotic selection should follow current local and national guidelines. Clinicians assess whether the patient can be treated as an outpatient or requires hospitalization.
For adults with community-acquired pneumonia and no major comorbidities, commonly recommended options may include:
Amoxicillin.
Doxycycline.
A macrolide in selected settings where resistance is appropriately low.
For outpatients with relevant comorbidities, treatment may include a beta-lactam plus doxycycline or a macrolide, or a respiratory fluoroquinolone when appropriate.
Common respiratory fluoroquinolones include levofloxacin and moxifloxacin. Their use should consider serious adverse effects, drug interactions, and individual risk factors.
Monitor temperature, respiratory rate, oxygen saturation, mental status, and hydration. Assess the patient’s response to antimicrobial therapy and watch for worsening hypoxemia or sepsis.
Patients should complete the prescribed antibiotic course unless their clinician changes the treatment plan. Antibiotics should not be used for viral pneumonia unless a bacterial infection is also suspected or confirmed.
Pediatric pneumonia treatment depends heavily on the child’s age, clinical severity, vaccination status, and likely pathogen.
Possible pathogens include Chlamydia trachomatis, respiratory viruses, and other organisms. Infants in this age group require careful evaluation because serious bacterial infection may be present.
Macrolides such as azithromycin may be used when Chlamydia trachomatis infection is suspected. Hospital evaluation and specialist guidance may be needed.
Viruses are common causes of pneumonia in young children, while Streptococcus pneumoniae remains an important bacterial pathogen.
When bacterial pneumonia is suspected, amoxicillin is commonly used for appropriately selected outpatient cases. Severe illness may require intravenous antibiotics such as ceftriaxone or other guideline-directed therapy.
Atypical pathogens, including Mycoplasma pneumoniae, become more relevant in school-aged children and adolescents.
Macrolides may be used when an atypical bacterial infection is suspected. Treatment should be based on clinical assessment and local recommendations.
Tobacco cessation is one of the most effective ways to reduce respiratory disease progression and improve cardiovascular health. Quitting smoking reduces exposure to harmful substances and may slow lung function decline in people with COPD.
The most effective approach often combines behavioral support with pharmacologic treatment.
Nicotine replacement therapy provides controlled doses of nicotine without the toxic substances produced by burning tobacco.
Common forms include:
Nicotine patches.
Nicotine gum.
Nicotine lozenges.
Nicotine nasal spray.
Nicotine inhalers.
Patches provide longer-lasting nicotine delivery, while gum and lozenges can help manage breakthrough cravings. Combination NRT, such as a patch plus gum or lozenge, may be more effective than one form alone.
Patients should follow product-specific instructions. Nicotine gum is chewed slowly until a tingling sensation develops, then parked between the cheek and gum. Patients should avoid eating or drinking acidic beverages immediately before or during use when instructed by the product labeling.
Common adverse effects depend on the formulation and may include skin irritation, mouth irritation, nausea, insomnia, and vivid dreams.
Bupropion is a non-nicotine medication that affects neurotransmitter activity involved in nicotine dependence and cravings.
It may help reduce withdrawal symptoms and the urge to smoke.
Bupropion is contraindicated in patients with a seizure disorder and in those with certain eating disorders. It should not be used with monoamine oxidase inhibitors or in other situations specified by prescribing information.
Common adverse effects include insomnia, dry mouth, headache, and nausea.
Varenicline is a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor. It reduces nicotine cravings and decreases the rewarding effects of smoking.
Varenicline is one of the most effective single medications for smoking cessation.
Common adverse effects include nausea, abnormal dreams, insomnia, and headache. Renal function should be considered when determining the dose.
Behavioral counseling and follow-up support improve the likelihood of successful cessation.
Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. Pulmonary TB spreads primarily through airborne particles released by a person with infectious pulmonary or laryngeal disease.
Symptoms of active pulmonary TB may include:
Cough lasting several weeks.
Fever.
Night sweats.
Weight loss.
Fatigue.
Hemoptysis in some patients.
TB treatment requires multiple medications because the organism can develop resistance when therapy is inadequate or incomplete.
The traditional first-line drug regimen for drug-susceptible pulmonary TB includes:
Isoniazid (INH): Inhibits mycolic acid synthesis in susceptible mycobacteria.
Rifampin: Inhibits bacterial RNA synthesis.
Ethambutol: Inhibits cell wall-related processes and helps protect against resistance during the initial phase.
Pyrazinamide: Has important activity against TB organisms in acidic environments.
A commonly used regimen consists of an intensive phase with all four medications, followed by a continuation phase using isoniazid and rifampin when appropriate.
Treatment duration is often six months for drug-susceptible pulmonary TB, although the regimen and duration depend on drug susceptibility, disease site, clinical factors, and current guidelines.
TB therapy requires regular clinical monitoring to assess treatment response, adherence, and adverse effects.
Important adverse effects include hepatotoxicity and peripheral neuropathy.
Patients should report:
Loss of appetite.
Nausea or vomiting.
Dark urine.
Jaundice.
Unusual fatigue.
Numbness or tingling in the hands and feet.
Pyridoxine (vitamin B6) supplementation is often prescribed for patients at increased risk of isoniazid-associated neuropathy.
Rifampin may cause orange or reddish discoloration of urine, tears, and other body fluids. This is a common and generally harmless effect.
However, rifampin has numerous drug interactions because it induces hepatic drug-metabolizing enzymes. It may reduce the effectiveness of hormonal contraceptives and other medications.
Ethambutol can cause optic neuritis. Patients should report blurred vision, changes in color perception, or visual disturbances promptly.
Baseline and follow-up vision assessments may be appropriate depending on treatment duration and clinical risk.
Pyrazinamide may cause hepatotoxicity and hyperuricemia. Monitor for joint pain, gout-like symptoms, and liver-related adverse effects.
The specific monitoring schedule depends on the regimen and patient risk factors. Baseline assessment and periodic follow-up may include:
Liver function tests.
Serum creatinine and renal function.
Complete blood count when clinically indicated.
Visual assessment for patients receiving ethambutol.
Sputum smear and culture monitoring for pulmonary TB.
Monthly clinical assessments are important for evaluating adherence, symptoms, adverse effects, and treatment response.
Patients should be taught not to stop TB medication without medical guidance because incomplete treatment increases the risk of treatment failure and drug resistance.
Latent TB infection occurs when a person is infected with Mycobacterium tuberculosis but does not have active TB disease. Patients generally have no symptoms and cannot spread TB through the air simply because they have latent infection.
Treatment reduces the risk of developing active TB disease. Current CDC guidance commonly prefers shorter rifamycin-based regimens when appropriate, such as three months of once-weekly isoniazid plus rifapentine or four months of daily rifampin.
Treatment selection depends on age, drug interactions, pregnancy considerations, HIV status, and other clinical factors.
Patients should understand the difference between latent TB infection and active TB disease. Education should emphasize adherence, medication safety, and prompt reporting of adverse effects.
Monthly clinical monitoring is commonly recommended during preventive therapy.
Inhaled corticosteroids are the foundation of long-term asthma control.
SABA-only treatment is not the preferred long-term asthma strategy for adults and adolescents.
LABAs must be combined with ICS in asthma but may be used alone in COPD.
LAMAs are important maintenance bronchodilators for COPD.
COPD diagnosis is confirmed with appropriate spirometry, including a post-bronchodilator FEV1/FVC ratio below 0.70.
Smoking cessation is the most effective intervention for reducing ongoing tobacco-related lung damage.
Pneumonia treatment depends on age, severity, comorbidities, and likely pathogens.
Tuberculosis requires multidrug therapy and careful monitoring for adverse effects.
Isoniazid is associated with hepatotoxicity and peripheral neuropathy.
Ethambutol requires attention to visual changes.
Rifampin causes orange body fluid discoloration and significant drug interactions.
Patient education, adherence, and follow-up are essential for successful respiratory disease management.
A short-acting beta-agonist provides rapid bronchodilation for relief of acute bronchospasm. A long-acting beta-agonist provides prolonged bronchodilation for maintenance treatment. In asthma, LABAs must be used with an inhaled corticosteroid.
Inhaled corticosteroids reduce airway inflammation, decrease asthma exacerbations, and improve long-term symptom control. They treat the underlying inflammatory process rather than only relaxing airway smooth muscle.
LAMAs may be added to ICS-containing treatment for selected patients whose asthma remains uncontrolled despite optimized therapy. Tiotropium is an example of a LAMA used in asthma.
COPD is confirmed using spirometry in the appropriate clinical setting. A post-bronchodilator FEV1/FVC ratio below 0.70 supports persistent airflow obstruction.
Stopping smoking reduces ongoing exposure to harmful substances, slows smoking-related lung function decline, and improves overall health. It is the most important intervention for reducing the impact of tobacco on COPD progression.
Traditional first-line treatment for drug-susceptible pulmonary TB includes isoniazid, rifampin, pyrazinamide, and ethambutol during the initial phase. Continuation therapy depends on the patient’s clinical circumstances and current TB guidelines.
Varenicline, combination nicotine replacement therapy, and bupropion are effective options. The best choice depends on medical history, contraindications, preferences, and access to behavioral support.
Asthma management prioritizes ICS-containing treatment to control airway inflammation and prevent exacerbations. COPD treatment focuses on bronchodilators, smoking cessation, pulmonary rehabilitation, and oxygen therapy when indicated. Pneumonia requires appropriate antimicrobial therapy based on the patient’s age, clinical condition, and likely pathogen. Tuberculosis requires prolonged multidrug therapy with careful monitoring for hepatotoxicity, drug interactions, visual changes, and other adverse effects.
For nursing students, understanding medication mechanisms, adverse effects, contraindications, and patient education is essential for safe pharmacologic management. Evidence-based guidelines should be used to guide treatment decisions, and patients should receive individualized education to promote adherence and improve respiratory outcomes.
